MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 4, 2006; DOI: 10.1124/mol.106.027474


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.027474v1
70/5/1481    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dale, Y. R
Right arrow Articles by Eltom, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dale, Y. R
Right arrow Articles by Eltom, S. E.


Received for publication June 5, 2006.
Revised July 12, 2006.
Accepted for publication August 4, 2006.

Calpain mediates the dioxin-induced activation and down-regulation of the aryl hydrocarbon receptor

Yolanda R Dale 1 Sakina E. Eltom 1*

1 Meharry Medical College

* Address correspondence to: E-mail: seltom{at}mmc.edu

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand-activated basic-helix-loop-helix (bHLH) transcription factor that binds polyaromatic hydrocarbons (PAH), such as dioxin, and mediates their toxicity. Binding of PAH to AhR in the cytoplasm triggers a poorly defined transformation step of the receptor into a nuclear transcription factor. In this study, we show that the calcium-dependent cysteine protease, calpain, plays a major role in the ligand-induced transformation and signaling of AhR. Fluorescence imaging measurements showed that TCDD treatment elevates intracellular calcium, providing the trigger for calpain activation, as measured towards BOC-LM-CMAC, a calpain-specific substrate. Inhibition of calpain activity by the MDL28170 blocked the TCDD-induced nuclear translocation of AhR in Hepa1c1c7 mouse hepatoma cell line. Treatment of the human metastatic breast carcinoma cell line MT-2 with MDL28170 and PD 150606, two calpain-selective inhibitors, completely abolished the TCDD-induced transactivation of AhR as assessed by transcription of CYP1A1 gene. Previous studies have established that following TCDD-induced transactivation, the AhR undergoes a massive depletion; we show here that selective calpain inhibitors can block this step, suggesting that the ligand-induced down-regulation of the AhR is calpain-dependent. The data presented support a major role for calpain in the AhR transformation, transactivation and subsequent down-regulation, and provide a possible explanation for many of the reported phenomena of ligand-independent activation of AhR.


Key words: Regulation of gene expression, Regulation - transcriptional, Ah receptor


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
P. Monteiro, D. Gilot, E. Le Ferrec, C. Rauch, D. Lagadic-Gossmann, and O. Fardel
Dioxin-Mediated Up-Regulation of Aryl Hydrocarbon Receptor Target Genes Is Dependent on the Calcium/Calmodulin/CaMKI{alpha} Pathway
Mol. Pharmacol., March 1, 2008; 73(3): 769 - 777.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. S. Pollenz
Comments on "Calpain Mediates the Dioxin-Induced Activation and Down-Regulation of the Aryl Hydrocarbon Receptor"
Mol. Pharmacol., January 1, 2007; 71(1): 384 - 385.
[Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. E. Eltom and Y. Dale
Response to Comments on "Calpain Mediates the Dioxin-Induced Activation and Down-Regulation of the Aryl Hydrocarbon Receptor"
Mol. Pharmacol., January 1, 2007; 71(1): 386 - 387.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics